Anti-Malaria Prophylaxis for Pregnancy (AMPROP) Clinical Trial
- Conditions
- Malaria
- Registration Number
- PACTR202104622127025
- Lead Sponsor
- igerian Institute of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 200
A. HIV POSITIVE POPULATION
1.HIV positive pregnant women
2. Above 13wks gestational age
3. Afebrile at the time of recruitment
4.Not sensitive to sulphadozine
5. Not sensitive to standard ITN
6.Not sensitive to mefloquine
B. HIV NEGATIVE POPULATION
1.HIV negative pregnant women
2. Above 13wks gestational age
3. Afebrile at the time of recruitment
4.Not sensitive to sulphadozine
5. Not sensitive to mefloquine
6. Not sensitive to standard ITN
A. HIV POSITIVE POPULATION
1. SCD IN PREGNANCY
2. Known febrile illness in the Index pregnancy
3. Known sensitivity to sulphadozine/pyrimethamine combination
4. Known sensitive to mefloquine
B. HIV NEGATIVE POPULATION
1. SCD IN PREGNANCY
2. Known febrile illness in the Index pregnancy
3. Known sensitivity to sulphadozine/pyrimethamine
4. Known sensitivity to mefloquine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.